The Role of Minimal Residual Disease Measurements in the Therapy for CLL. Is It Ready for Prime Time?

Hematology/Oncology Clinics of North America

Volumn 27, Issue 2, 2013, Pages 267-288

  Böttcher, Sebastian ^a   Hallek, Michael ^b   Ritgen, Matthias ^a   Kneba, Michael ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Allele specific oligonucleotide IGH real time quantitative polymerase chain reaction; Chronic lymphocytic leukemia; Minimal residual disease; MRD flow; Prognostic factors; Progression free survival

Indexed keywords

ALEMTUZUMAB; CD19 ANTIGEN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; DISEASE MARKER; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN GENE; LEUKEMIA CELL; LIMIT OF DETECTION; MEASUREMENT; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM, RESIDUAL; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84875781702     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.01.005     Document Type: Review

References (70)

1. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747):1164-1174.
2. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107(3):885-891.
3. Fischer K., Cramer P., Busch R., et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011, 29(26):3559-3566.
4. Fischer K., Cramer P., Busch R., et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012, 30(26):3209-3216.
5. Knauf W.U., Lissichkov T., Aldaoud A., et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27(26):4378-4384.
6. Knauf W.U., Lissitchkov T., Aldaoud A., et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 2012, 159(1):67-77.
7. Catovsky D., Richards S., Matutes E., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370(9583):230-239.
8. Flinn I.W., Neuberg D.S., Grever M.R., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007, 25(7):793-798.
9. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112(4):975-980.
10. Mateos M.V., Oriol A., Martinez-Lopez J., et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 2012, 120(13):2581-2588.
11. Sonneveld P., Schmidt-Wolf I.G., van der Holt B., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012, 30(24):2946-2955.
12. Mateos M.V., Richardson P.G., Schlag R., et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010, 28(13):2259-2266.
13. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359(9):906-917.
14. Palumbo A., Bringhen S., Rossi D., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010, 28(34):5101-5109.
15. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106(12):3725-3732.
16. Salles G., Seymour J.F., Offner F., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377(9759):42-51.
17. Martinelli G., Schmitz S.F., Utiger U., et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010, 28(29):4480-4484.
18. van Oers M.H., Van Glabbeke M., Giurgea L., et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010, 28(17):2853-2858.
19. Marcus R., Imrie K., Solal-Celigny P., et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008, 26(28):4579-4586.
20. Kluin-Nelemans H.C., Hoster E., Hermine O., et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012, 367(6):520-531.
21. Forstpointner R., Unterhalt M., Dreyling M., et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108(13):4003-4008.
22. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112(7):2687-2693.
23. Lamanna N., Jurcic J.G., Noy A., et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009, 27(4):491-497.
24. van Dongen J.J., Langerak A.W., Bruggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003, 17(12):2257-2317.
25. Bottcher S., Ritgen M., Buske S., et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008, 93(4):551-559.
26. Bottcher S., Ritgen M., Pott C., et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004, 18(10):1637-1645.
27. Moreno C., Villamor N., Colomer D., et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 107(11):4563-4569.
28. Bosch F., Ferrer A., Villamor N., et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008, 14(1):155-161.
29. Rawstron A.C., Kennedy B., Evans P.A., et al. Quantitation of minimal residual disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29-35.
30. Voena C., Ladetto M., Astolfi M., et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997, 11(10):1793-1798.
31. Noy A., Verma R., Glenn M., et al. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. Blood 2001, 97(7):1929-1936.
32. Farina L., Carniti C., Dodero A., et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009, 94(5):654-662.
33. Bruggemann M., van der Velden V., Raff T., et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 2004, 18(4):709-719.
34. van der Velden V.H., Hochhaus A., Cazzaniga G., et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17(6):1013-1034.
35. van der Velden V.H., Cazzaniga G., Schrauder A., et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007, 21(4):604-611.
36. Cabezudo E., Matutes E., Ramrattan M., et al. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997, 11(11):1909-1914.
37. Vuillier F., Claisse J.F., Vandenvelde C., et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma 1992, 7(3):195-204.
38. Robertson L.E., Huh Y.O., Butler J.J., et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992, 80(1):29-36.
39. Lenormand B., Bizet M., Fruchart C., et al. Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. Leukemia 1994, 8(6):1019-1026.
40. Rawstron A.C., Bottcher S., Letestu R., et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013, 27:142-149.
41. Bomberger C., Singh-Jairam M., Rodey G., et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 1998, 91(7):2588-2600.
42. Rawstron A.C., de Tute R., Jack A.S., et al. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 2006, 20(12):2102-2110.
43. Rawstron A.C., Villamor N., Ritgen M., et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007, 21(5):956-964.
44. Bottcher S., Stilgenbauer S., Busch R., et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009, 23(11):2007-2017.
45. Böttcher S., Ritgen M., Fischer K., et al. Minimal residual disease quantification is an independent predictor of progression free and overall survival in chronic lymphocytic leukemia. A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012, 30:980-988.
46. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(12):5446-5456.
47. Logan A.C., Gao H., Wang C., et al. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A 2011, 108(52):21194-21199.
48. Hillmen P., Skotnicki A.B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25(35):5616-5623.
49. Kay N.E., Geyer S.M., Call T.G., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007, 109(2):405-411.
50. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23(18):4070-4078.
51. Schweighofer C.D., Ritgen M., Eichhorst B.F., et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009, 144(1):95-98.
52. Ritgen M., Stilgenbauer S., von Neuhoff N., et al. Graft versus leukemia effect may overcome therapeutic resistance of chronic lymphocytic leukemia with unmuted variable immunoglobulin heavy chain status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004, 104:2600-2602.
53. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23(13):2971-2979.
54. Milligan D.W., Fernandes S., Dasgupta R., et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005, 105(1):397-404.
55. Goodman M. Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard?. J Clin Oncol 2005, 23(28):7240-7241.
56. Kwok M., Rawstron A.C., Varghese A.M., et al. Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (CLL) that is independent of the type or line of therapy. Blood 2009, 114:540. [abstract].
57. Bottcher S., Ritgen M., Fischer K., et al. Minimal residual disease (MRD) re-growth kinetics are an independent predictor for progression free survival (PFS) in chronic lymphocytic leukemia (CLL) and are related to biologically defined CLL-subgroups- results from the CLL8 trial of the German CLL Study Group (GCLLSG) [abstract]. Blood 2011, 118:1777.
58. Ritgen M., Lange A., Stilgenbauer S., et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003, 101(5):2049-2053.
59. Fink A., Busch R., Pflug N., et al. Prediction of poor outcome in CLL patients treated with FCR (fludarabine, cyclophosphamide, rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG) [abstract]. Blood 2011, 118:977.
60. Pettitt A.R., Jackson R., Carruthers S., et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012, 30(14):1647-1655.
61. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107(3):1116-1123.
62. Rawstron A.C., Kennedy B., Moreton P., et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004, 103(6):2027-2031.
63. Parikh S.A., Keating M.J., O'Brien S., et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011, 118(8):2062-2068.
64. Maloum K., Settegrana C., Chapiro E., et al. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Ann Hematol 2009, 88(12):1215-1221.
65. Ritgen M., Bottcher S., Stilgenbauer S., et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008, 22(7):1377-1386.
66. Dreger P., Dohner H., Ritgen M., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010, 116(14):2438-2447.
67. Caballero D., Garcia-Marco J.A., Martino R., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005, 11(21):7757-7763.
68. Bottcher S., Ritgen M., Dreger P. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. Blood Rev 2011, 25(2):91-96.
69. Langerak A.W., Groenen P.J., Bruggemann M., et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012, 26(10):2159-2171.
70. Ysebaert L., Gross E., Kuhlein E., et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 2010, 24(7):1310-1316.